TY - JOUR
T1 - Dual-Isotope SPECT Imaging with NIS Reporter Gene and Duramycin to Visualize Tumor Susceptibility to Oncolytic Virus Infection
AU - Zhang, Lianwen
AU - Suksanpaisan, Lukkana
AU - Jiang, Huailei
AU - DeGrado, Timothy R.
AU - Russell, Stephen J.
AU - Zhao, Ming
AU - Peng, Kah Whye
N1 - Funding Information:
We thank Teresa Decklever and Dianna Glynn of the Mayo Clinic Nuclear Medicine Molecular Imaging Resource for their expert help in image acquisition. This study is supported by National Institutes of Health (R01 CA175795 ) and Mayo Foundation .
Funding Information:
We thank Teresa Decklever and Dianna Glynn of the Mayo Clinic Nuclear Medicine Molecular Imaging Resource for their expert help in image acquisition. This study is supported by National Institutes of Health (R01 CA175795) and Mayo Foundation.
Publisher Copyright:
© 2019 The Author(s)
PY - 2019/12/20
Y1 - 2019/12/20
N2 - Noninvasive dual-imaging methods that provide an early readout on tumor permissiveness to virus infection and tumor cell death could be valuable in optimizing development of oncolytic virotherapies. Here, we have used the sodium iodide symporter (NIS) and 125I radiotracer to detect infection and replicative spread of an oncolytic vesicular stomatitis virus (VSV) in VSV-susceptible (MPC-11 tumor) versus VSV-resistant (CT26 tumor) tumors in BALB/c mice. In conjunction, tumor cell death was imaged simultaneously using technetium (99mTc)-duramycin that binds phosphatidylethanolamine in apoptotic and necrotic cells. Dual-isotope single-photon emission computed tomography/computed tomography (SPECT/CT) imaging showed areas of virus infection (NIS and 125I), which overlapped well with areas of tumor cell death (99mTc-duramycin imaging) in susceptible tumors. Multiple infectious foci arose early in MPC-11 tumors, which rapidly expanded throughout the tumor parenchyma over time. There was a dose-dependent increase in numbers of infectious centers and 99mTc-duramycin-positive areas with viral dose. In contrast, NIS or duramycin signals were minimal in VSV-resistant CT26 tumors. Combinatorial use of NIS and 99mTc-duramycin SPECT imaging for simultaneous monitoring of oncolytic virotherapy (OV) spread and the presence or absence of treatment-associated cell death could be useful to guide development of combination treatment strategies to enhance therapeutic outcome.
AB - Noninvasive dual-imaging methods that provide an early readout on tumor permissiveness to virus infection and tumor cell death could be valuable in optimizing development of oncolytic virotherapies. Here, we have used the sodium iodide symporter (NIS) and 125I radiotracer to detect infection and replicative spread of an oncolytic vesicular stomatitis virus (VSV) in VSV-susceptible (MPC-11 tumor) versus VSV-resistant (CT26 tumor) tumors in BALB/c mice. In conjunction, tumor cell death was imaged simultaneously using technetium (99mTc)-duramycin that binds phosphatidylethanolamine in apoptotic and necrotic cells. Dual-isotope single-photon emission computed tomography/computed tomography (SPECT/CT) imaging showed areas of virus infection (NIS and 125I), which overlapped well with areas of tumor cell death (99mTc-duramycin imaging) in susceptible tumors. Multiple infectious foci arose early in MPC-11 tumors, which rapidly expanded throughout the tumor parenchyma over time. There was a dose-dependent increase in numbers of infectious centers and 99mTc-duramycin-positive areas with viral dose. In contrast, NIS or duramycin signals were minimal in VSV-resistant CT26 tumors. Combinatorial use of NIS and 99mTc-duramycin SPECT imaging for simultaneous monitoring of oncolytic virotherapy (OV) spread and the presence or absence of treatment-associated cell death could be useful to guide development of combination treatment strategies to enhance therapeutic outcome.
UR - http://www.scopus.com/inward/record.url?scp=85074645818&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074645818&partnerID=8YFLogxK
U2 - 10.1016/j.omto.2019.10.002
DO - 10.1016/j.omto.2019.10.002
M3 - Article
AN - SCOPUS:85074645818
SN - 2372-7705
VL - 15
SP - 178
EP - 185
JO - Molecular Therapy - Oncolytics
JF - Molecular Therapy - Oncolytics
ER -